- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Wegovy pill shows strong early uptake, as rival looms | ||
| Fr | Sanofi linked to takeover bid for Ocular Therapeutix | ||
| Fr | Ocugen shares fall, despite positive eye disorder trial | ||
| Fr | Autonomous AI can spot cognitive decline in medical notes | ||
| Fr | Trump's affordability plan arrives, built around MFN pricing | ||
| Do | J&J builds case for earlier Tecvayli use in multiple myeloma | ||
| Do | Novartis issues a life sciences warning in a 'G-Zero' world | ||
| Do | Novo Nordisk Foundation pledges €736m for European biotech | ||
| Do | EMA and FDA agree 'principles' for AI in drug development | ||
| Do | Oxford BioMedica confirms private equity takeover talks | ||
| Mi | JPM: Novo Nordisk CEO gives insight into new strategy | ||
| Mi | FDA seeks changes to GLP-1, flu shot labels | ||
| Mi | Hippocratic AI builds in life sciences with Grove AI buy | ||
| Mi | JPM: Illumina launches 'unprecedented' disease biology atlas | ||
| Mi | UK names health data chief, as BIA finds its new CEO | ||
| Di | JPM: Anthropic reveals its answer to ChatGPT for Health | ||
| Di | Sentynl gets first FDA approval for rare disease Menkes | ||
| Di | AbbVie turbocharges its US investment promise to $100bn | ||
| Di | JPM: Is the UK's clinical trials sector turning a corner? | ||
| 12.01. | JPM: AbbVie pays $650m upfront for RemeGen cancer drug | ||
| 12.01. | FDA removes barriers to cell, gene therapy development | ||
| 12.01. | Abivax climbs on Lilly takeover speculation | ||
| 12.01. | Madrigal eyes combination MASH therapy with Pfizer deal | ||
| 12.01. | Perlmutter's Eikon follows the IPO trail | ||
| 09.01. | J&J jumps on the MFN pricing train |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .